TACE plus camrelizumab and apatinib

COMBINATION_PRODUCT2 trials

Conditions

ApatinibCamrelizumabHepatocellular Carcinoma (HCC)Liver Cancer AdultTransarterial ChemoembolizationUnresectable Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma (HCC)

Phase 2

FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma

Not yet recruitingNCT07314372

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolHepatocellular Carcinoma (HCC), Liver Cancer Adult, Unresectable Hepatocellular Carcinoma (HCC)

Start: 2026-02-01End: 2028-12-01Target: 86Updated: 2026-01-20

Phase 3

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

RecruitingNCT06485466

Guohui XuApatinib, Camrelizumab, Transarterial Chemoembolization +1

Start: 2024-07-01End: 2028-06-30Target: 101Updated: 2024-07-03

TACE plus camrelizumab and apatinib

Sponsors

Conditions

Phase 2

Phase 3